The prodrug platin-A: simultaneous release of cisplatin and aspirin.
Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.
NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602 (USA) http://shanta.chem.uga.edu.
Rakesh K
RK
Pathak
Sean
S
Marrache
Joshua H
JH
Choi
Trenton B
TB
Berding
Shanta
S
Dhar
D061605:Administration, Intravenous; D001241:Aspirin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011355:Prodrugs / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics
D011355:Prodrugs; D002945:Cisplatin; D001241:Aspirin
antitumor agents; drug design; inflammation; platinum; prodrugs